Related Experiment Video
Updated: May 16, 2026

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Antidiabetic plants and their active constituents.
1Department of Botany, Brandon University, Brandon, MB R7A 6A9, CANADA.
Summary
Traditional herbal remedies offer promising alternatives for managing diabetes mellitus, especially in rural areas. Research into over 1200 plant species reveals diverse hypoglycemic compounds and potential for developing affordable antidiabetic drugs.
Area of Science:
- Ethnobotany
- Pharmacology
- Drug Discovery
Background:
- Diabetes mellitus is a growing global health concern, particularly in rural populations.
- Current therapies for diabetes are often inadequate, costly, and inaccessible in developing regions.
- Traditional herbal medicine presents a potential source for novel antidiabetic treatments.
Purpose of the Study:
- To review plants used traditionally for diabetes treatment and scientifically investigated for antidiabetic activity.
- To explore the diversity of plant constituents with hypoglycemic effects and their mechanisms of action.
- To guide the development of affordable, plant-derived antidiabetic drugs and novel therapeutic compounds.
Main Methods:
- Comprehensive literature review of over 1200 plant species.
- Analysis of ethnobotanical data and scientific investigations on antidiabetic activity.
- Examination of hypoglycemic constituents, bioassay methods, and toxicity profiles.
Main Results:
- Identification of numerous plant species with reported antidiabetic properties.
- Documentation of a wide array of plant-derived compounds exhibiting hypoglycemic activity.
- Overview of established bioassay techniques and potential safety concerns.
Conclusions:
- Botanical resources can serve as a foundation for developing cost-effective antidiabetic medications.
- Further research into antidiabetic plants may lead to the discovery of new hypoglycemic drug leads.
- Ethnobotanical knowledge is crucial for identifying and validating potential plant-based therapies for diabetes.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...